Ovid Therapeutics Details 2024 Executive Equity Compensation

TL;DR

**OVID's 2024 proxy statement reveals standard executive equity grants, signaling business as usual; no major red flags, but no catalysts either.**

AI Summary

Ovid Therapeutics Inc.'s DEF 14A filing, dated May 22, 2025, primarily details executive compensation and equity award information for the fiscal year ended December 31, 2024. While specific revenue and net income figures are not explicitly provided in this excerpt, the document focuses on the structure of compensation for both named executive officers (PEO) and non-named executive officers (Non-PEO/NEO). Key business changes and strategic outlook are not detailed in this specific filing, which is a proxy statement. The filing indicates grants of employee stock options to individuals like Margaret Alexander and Jeffrey Rona on July 30, 2024, and to Margaret Alexander again on September 9, 2024. The risk section is not elaborated in this excerpt, but the strategic outlook is implicitly tied to incentivizing leadership through equity. The document outlines adjustments to equity awards, including option and stock awards, for both PEO and Non-PEO/NEO categories for the 2024 fiscal year.

Why It Matters

This DEF 14A filing provides crucial transparency into Ovid Therapeutics' executive compensation practices, particularly regarding equity awards for 2024. For investors, understanding how executives are incentivized through stock options and awards is vital for assessing alignment with shareholder interests and potential dilution. Employees, especially those in leadership, gain insight into the company's compensation philosophy and the value placed on their contributions. In the competitive pharmaceutical industry, attractive compensation packages are essential for retaining top talent, directly impacting Ovid's ability to innovate and compete effectively against larger players. The structure of these awards can signal the company's long-term growth strategy.

Risk Assessment

Risk Level: low — The filing is a routine DEF 14A proxy statement, primarily detailing executive compensation and equity awards for 2024. It does not introduce new operational or financial risks, nor does it indicate any immediate threats to Ovid Therapeutics Inc.'s business model. The information presented is standard for corporate governance disclosures.

Analyst Insight

Investors should review the full DEF 14A to understand the complete compensation packages and voting proposals for the upcoming annual meeting. Pay close attention to the performance metrics tied to executive equity awards to gauge alignment with long-term shareholder value. This filing alone doesn't warrant immediate trading action but provides context for governance and management incentives.

Executive Compensation

Key Numbers

• 2024-12-31 — Fiscal Year End (The period covered by the compensation data in the filing.)
• 2025-05-22 — Filing Date (Date the DEF 14A was officially filed with the SEC.)
• 001-38085 — SEC File Number (Unique identifier for Ovid Therapeutics Inc.'s SEC filings.)
• 1934 Act — SEC Act (The Securities Exchange Act under which the filing is made.)
• 22 — Public Document Count (Number of public documents associated with this filing.)

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant filing the DEF 14A
• Margaret Alexander (person) — Recipient of employee stock options on July 30, 2024, and September 9, 2024
• Jeffrey Rona (person) — Recipient of employee stock options on July 30, 2024
• SEC (regulator) — United States Securities and Exchange Commission
• 0001636651 (company) — Central Index Key (CIK) for Ovid Therapeutics Inc.
• 441 Ninth Avenue, 14th Floor, New York, NY 10001 (company) — Business address of Ovid Therapeutics Inc.
• 212-776-4381 (company) — Business phone number of Ovid Therapeutics Inc.
• December 31, 2024 (date) — Conformed period of report end date
• May 22, 2025 (date) — Filed as of date for the DEF 14A
• Pharmaceutical Preparations (company) — Standard Industrial Classification (SIC) for Ovid Therapeutics Inc.

FAQ

Industry Context

Ovid Therapeutics Inc. operates within the pharmaceutical preparations sector, focusing on the development of novel therapeutics. This industry is characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory oversight from bodies like the FDA. Companies in this space often rely on strategic partnerships and equity-based compensation to attract and retain key scientific and executive talent.

Regulatory Implications

As a pharmaceutical company, Ovid Therapeutics is subject to stringent regulations governing drug development, clinical trials, and marketing. Compliance with FDA guidelines and other health authorities is critical. Changes in regulatory landscapes or failure to meet compliance standards can significantly impact the company's operations and the value of its equity awards.

What Investors Should Do

1. [object Object]
2. [object Object]

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the period for which compensation data is reported.
• 2025-05-22: Filing Date — The date the DEF 14A proxy statement was officially submitted to the SEC.
• 2024-07-30: Stock Option Grant — Date when employee stock options were granted to Margaret Alexander and Jeffrey Rona.
• 2024-09-09: Stock Option Grant — Date when additional employee stock options were granted to Margaret Alexander.

Glossary

DEF 14A

A definitive proxy statement filed with the SEC by public companies, typically concerning annual meetings of shareholders, including executive compensation details. (This document is the primary source of information regarding executive compensation and equity awards for Ovid Therapeutics Inc. for the fiscal year 2024.)

PEO

Principal Executive Officer, referring to the highest-ranking executive in a company, typically the CEO. (Used to categorize executive compensation and equity award adjustments for the top executive.)

Non-PEO/NEO

Non-Principal Executive Officer/Named Executive Officer, referring to other key executives in the company who are not the PEO. (Used to categorize executive compensation and equity award adjustments for other named executives.)

Employee Stock Option

A contract that gives an employee the right, but not the obligation, to purchase a company's stock at a predetermined price (the strike price) within a specified period. (Details specific grants of these options to executives, indicating a form of incentive-based compensation.)

Equity Awards Adjustments

Changes made to the value or terms of stock options or other equity-based awards granted to employees. (The filing indicates that such adjustments were made for both PEO and Non-PEO/NEO categories in fiscal year 2024.)

Year-Over-Year Comparison

This filing, a DEF 14A, primarily details executive compensation and equity awards for the fiscal year ending December 31, 2024. Specific year-over-year financial metric comparisons (revenue, net income, margins) are not available within this document. However, the focus on equity grants to key executives like Margaret Alexander and Jeffrey Rona suggests a continued strategy of incentivizing leadership through stock-based compensation, a common practice in the biopharmaceutical industry.

From the Filing

0001628280-25-027146.txt : 20250522 0001628280-25-027146.hdr.sgml : 20250522 20250522080433 ACCESSION NUMBER: 0001628280-25-027146 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 25974763 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 DEF 14A 1 ovid-20250521.htm DEF 14A ovid-20250521 DEF 14A FALSE 0001636651 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure 0001636651 2024-01-01 2024-12-31 0001636651 us-gaap:EmployeeStockOptionMember ovid:MargaretAlexanderMember 2024-07-30 0001636651 us-gaap:EmployeeStockOptionMember ovid:JeffreyRonaMember 2024-07-30 0001636651 us-gaap:EmployeeStockOptionMember ovid:MargaretAlexanderMember 2024-09-09 0001636651 2023-01-01 2023-12-31 0001636651 2022-01-01 2022-12-31 0001636651 ovid:EquityAwardsAdjustmentsExcludingValueReportedInTheCompensationTableOptionAwardsMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ovid:EquityAwardsAdjustmentsExcludingValueReportedInTheCompensationTableOptionAwardsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ovid:EquityAwardsAdjustmentsExcludingValueReportedInTheCompensationTableStockAwardsMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ovid:EquityAwardsAdjustmentsExcludingValueReportedInTheCompensationTableStockAwardsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001636651 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001636651 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) ______________________________________________________ Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Ovid Therapeutics Inc. (Name of Registrant